[A22-61] Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V

Last updated 01.12.2022

Project no.:

Commission awarded on 25.05.2022 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adults with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD1 or PD-L1 inhibitor

Result of dossier assessment:
  • Patients for whom chemotherapy is suitable: hint of minor added benefit
  • Patients for whom chemotherapy is unsuitable: added benefit not proven

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2022-12-01 A G-BA decision was published.
G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form